ATN1 and PRRC2A |
atrophin 1 |
proline-rich coiled-coil 2A |
|
|
|
|
|
|
ATN1 and BAG6 |
atrophin 1 |
BCL2-associated athanogene 6 |
|
|
|
|
|
|
TSC22D3 and NFKB1 |
TSC22 domain family, member 3 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- Ion channel transport
- Stimuli-sensing channels
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
TSC22D3 and MAD1L1 |
TSC22 domain family, member 3 |
MAD1 mitotic arrest deficient-like 1 (yeast) |
- Ion channel transport
- Stimuli-sensing channels
|
- Mitotic Spindle Checkpoint
- Amplification of signal from the kinetochores
- Mitotic Prometaphase
- Separation of Sister Chromatids
- Resolution of Sister Chromatid Cohesion
- Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
- Cell Cycle Checkpoints
- Mitotic Anaphase
- Mitotic Metaphase and Anaphase
- Cell Cycle, Mitotic
- M Phase
|
|
|
|
|
E2F1 and NFKB1 |
E2F transcription factor 1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- Cellular Senescence
- Activation of BH3-only proteins
- Oncogene Induced Senescence
- Assembly of the pre-replicative complex
- Pre-NOTCH Transcription and Translation
- G2 Phase
- G1/S Transition
- G1/S-Specific Transcription
- Programmed Cell Death
- Pre-NOTCH Expression and Processing
- Mitotic G1-G1/S phases
- Intrinsic Pathway for Apoptosis
- E2F mediated regulation of DNA replication
- Signaling by NOTCH
- DNA Replication Pre-Initiation
- G1 Phase
- M/G1 Transition
- Regulation of DNA replication
- G0 and Early G1
- CDC6 association with the ORC:origin complex
- Cell Cycle, Mitotic
- Activation of NOXA and translocation to mitochondria
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- Activation of PUMA and translocation to mitochondria
- Association of licensing factors with the pre-replicative complex
- Mitotic G2-G2/M phases
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
E2F1 and CTDP1 |
E2F transcription factor 1 |
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) phosphatase, subunit 1 |
- Cellular Senescence
- Activation of BH3-only proteins
- Oncogene Induced Senescence
- Assembly of the pre-replicative complex
- Pre-NOTCH Transcription and Translation
- G2 Phase
- G1/S Transition
- G1/S-Specific Transcription
- Programmed Cell Death
- Pre-NOTCH Expression and Processing
- Mitotic G1-G1/S phases
- Intrinsic Pathway for Apoptosis
- E2F mediated regulation of DNA replication
- Signaling by NOTCH
- DNA Replication Pre-Initiation
- G1 Phase
- M/G1 Transition
- Regulation of DNA replication
- G0 and Early G1
- CDC6 association with the ORC:origin complex
- Cell Cycle, Mitotic
- Activation of NOXA and translocation to mitochondria
- Cyclin D associated events in G1
- Oxidative Stress Induced Senescence
- Activation of PUMA and translocation to mitochondria
- Association of licensing factors with the pre-replicative complex
- Mitotic G2-G2/M phases
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
|
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- RNA Polymerase II Transcription
- Abortive elongation of HIV-1 transcript in the absence of Tat
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Tat-mediated HIV elongation arrest and recovery
- RNA Polymerase II Pre-transcription Events
- Late Phase of HIV Life Cycle
- Pausing and recovery of Tat-mediated HIV elongation
- Formation of RNA Pol II elongation complex
- HIV elongation arrest and recovery
- HIV Life Cycle
- Pausing and recovery of HIV elongation
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- HIV Transcription Elongation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
|
|
|
|
EDN1 and BAG6 |
endothelin 1 |
BCL2-associated athanogene 6 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- G alpha (q) signalling events
- Signaling by GPCR
- GPCR downstream signaling
- Peptide ligand-binding receptors
- Gastrin-CREB signalling pathway via PKC and MAPK
- Class A/1 (Rhodopsin-like receptors)
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
|
|
|
|
|
EEF2 and DISC1 |
eukaryotic translation elongation factor 2 |
disrupted in schizophrenia 1 |
- Synthesis of diphthamide-EEF2
- Uptake and actions of bacterial toxins
- Translation
- Post-translational protein modification
- Peptide chain elongation
- Eukaryotic Translation Elongation
- Gamma carboxylation, hypusine formation and arylsulfatase activation
- Uptake and function of diphtheria toxin
|
|
|
|
|
|
EGFR and RIN2 |
epidermal growth factor receptor |
Ras and Rab interactor 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EGFR and ANKS1B |
epidermal growth factor receptor |
ankyrin repeat and sterile alpha motif domain containing 1B |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EIF4EBP1 and TCF4 |
eukaryotic translation initiation factor 4E binding protein 1 |
transcription factor 4 |
- IRS-mediated signalling
- mTOR signalling
- mTOR signalling
- mTORC1-mediated signalling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- Release of eIF4E
- Eukaryotic Translation Initiation
- PKB-mediated events
- Cap-dependent Translation Initiation
- PI3K Cascade
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Translation
- IRS-related events
- Release of eIF4E
- mTORC1-mediated signalling
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
- PKB-mediated events
- PI3K Cascade
|
- CDO in myogenesis
- Myogenesis
|
|
|
|
|
EIF5 and NRGN |
eukaryotic translation initiation factor 5 |
neurogranin (protein kinase C substrate, RC3) |
- Ribosomal scanning and start codon recognition
- GTP hydrolysis and joining of the 60S ribosomal subunit
- Translation
- Eukaryotic Translation Initiation
- Cap-dependent Translation Initiation
|
|
|
|
|
|
ELANE and CXCL12 |
elastase, neutrophil expressed |
chemokine (C-X-C motif) ligand 12 |
- Collagen degradation
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Class A/1 (Rhodopsin-like receptors)
- Signaling by ERBB4
- GPCR ligand binding
- Metabolic disorders of biological oxidation enzymes
- GPCR downstream signaling
- Nuclear signaling by ERBB4
- Peptide ligand-binding receptors
- Chemokine receptors bind chemokines
- G alpha (i) signalling events
|
- Pegfilgrastim
- Alpha-1-proteinase inhibitor
- Filgrastim
- Mdl 101,146
- ONO-6818
|
|
|
|
ELAVL1 and PTBP2 |
ELAV like RNA binding protein 1 |
polypyrimidine tract binding protein 2 |
- Regulation of mRNA stability by proteins that bind AU-rich elements
- HuR stabilizes mRNA
|
|
|
|
|
|
ELF1 and NFKB1 |
E74-like factor 1 (ets domain transcription factor) |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
ELF3 and NFKB1 |
E74-like factor 3 (ets domain transcription factor, epithelial-specific ) |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
EMD and SYNE1 |
emerin |
spectrin repeat containing, nuclear envelope 1 |
- Mitotic Prophase
- Nuclear Envelope Breakdown
- Depolymerisation of the Nuclear Lamina
- Nuclear Envelope Reassembly
- Clearance of Nuclear Envelope Membranes from Chromatin
- Mitotic Anaphase
- Initiation of Nuclear Envelope Reformation
- Mitotic Metaphase and Anaphase
- Cell Cycle, Mitotic
- M Phase
|
|
|
|
|
|
ENO1 and SUMO4 |
enolase 1, (alpha) |
small ubiquitin-like modifier 4 |
- Gluconeogenesis
- Glucose metabolism
- Myoclonic epilepsy of Lafora
- Glycogen storage diseases
- Glycolysis
- Metabolism of carbohydrates
|
|
|
|
|
|
ENO1 and MYOC |
enolase 1, (alpha) |
myocilin, trabecular meshwork inducible glucocorticoid response |
- Gluconeogenesis
- Glucose metabolism
- Myoclonic epilepsy of Lafora
- Glycogen storage diseases
- Glycolysis
- Metabolism of carbohydrates
|
|
|
|
|
|
ENO1 and SRC |
enolase 1, (alpha) |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Gluconeogenesis
- Glucose metabolism
- Myoclonic epilepsy of Lafora
- Glycogen storage diseases
- Glycolysis
- Metabolism of carbohydrates
|
|
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5\'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- RU82129
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric Acid
- RU81843
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
|
|
|